Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.

The board of directors appointed Warren Stone, currently president and chief operating officer, as CEO and a board member, effective Jan. 4, 2027.

Tony Zook, the current CEO, will transition to executive chair.

Following the announcement, the stock fell more than 12%.

NeoGenomics Sets Leadership Transition

As part of the transition, longtime Board Chair Lynn Tetrault will remain an independent director until the company's 2027 annual meeting, when she plans not to seek reelection.

Independent director Michael Kelly, who joined the board in 2020, will become lead independent director effective Jan. 4, 2027.

Preliminary Third-Quarter Revenue Reaches $209 Million

NeoGenomics expects to report third-quarter revenue of about $209 million. The company said next-generation sequencing testing revenue grew about 28% year over year.

NeoGenomics also reiterated its 2026 revenue guidance of $802 million to $806 million.

The company continues to expect a net loss of $42 million to $34 million and adjusted EBITDA of $56 million to $58 million.

Analysts Weigh Growth And Valuation

William Blair on Tuesday said NeoGenomics does not depend on a single product or indication for growth, distinguishing it from several industry peers.

Analyst Matt Larew said revenue growth is being supported by commercial execution, a shift toward higher-value oncology testing, a durable base of recurring menu testing and strong exposure to the community channel.

He added that upcoming product launches and new indications could provide additional growth in coming quarters and years.

William Blair said sustained financial improvement could support valuation expansion. However, the firm currently values NeoGenomics at about three times estimated 2027 sales, compared with roughly five times for close peers and 11 times for a broader peer group.

Larew attributed the discount to slower growth, inconsistent historical execution and an overhang tied to the nonclinical business.

William Blair reiterated its Market Perform rating. BTIG upgraded NeoGenomics from Neutral to Buy with a $28 price forecast. Needham maintained its Buy rating and raised its price forecast to $22 from $19.

NEO Price Action: NeoGenomics shares were down 12.15% at $16.80 at the time of publication on Tuesday, according to market data.

Trading activity was elevated. About 3.25 million shares changed hands Tuesday, compared with the 100-day average volume of 2.33 million shares.